Skip to main content
Premium Trial:

Request an Annual Quote

Roche, Evotec Partner on Protein Biomarkers for Cancer Drugs

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) –Roche and Evotec today announced a three-year agreement directed at biomarker discovery for use with oncology drugs under development by Roche.

Under the terms of the deal, Evotec will use its PhosphoScout platform for the discovery of protein phosphorylation biomarkers that may be used to determine the efficacy of targeted cancer drugs in patients and for dosing decisions.

The firms will conduct multiple biomarker programs for therapeutic antibodies or small-molecule inhibitors, and Roche will conduct clinical trials and assess the development of companion diagnostics for patient stratification. Evotec will receive undisclosed upfront and milestone payments for each program.

Further details of the deal were not disclosed.

PhosphoScout is a mass spectrometry-based platform for identifying and quantifying cellular phosphorylation events. According to Evotec, it offers unbiased systems-wide profiling of signaling pathways.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.